Inhibition of CXCL10 release by monomeric C3bi and C4b

Clinical and Experimental Immunology

Volumn 167, Issue 1, 2012, Pages 149-157

  Takeda, Y ^a   Kaneda, K ^b   Jimma, F ^b   Shiobara, N ^b   Hidaka, M ^c   Saniabadi, A R ^b   Wakabayashi, I ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b JAPAN IMMUNORESEARCH LABORATORIES   (Japan)

^c YASUDA WOMEN'S UNIVERSITY   (Japan)

Author keywords

Chemokine; Complement; Inflammatory disease; Leucocyte apheresis; Type I interferon

Indexed keywords

BETA INTERFERON; CELLULOSE ACETATE; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3BI; COMPLEMENT COMPONENT C4B; GAMMA INTERFERON INDUCIBLE PROTEIN 10; LIPOPOLYSACCHARIDE; MESSENGER RNA; STAT1 PROTEIN; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; LEUKOCYTE; MASS SPECTROMETRY; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION;

ANTI-INFLAMMATORY AGENTS; CELL ADHESION; CELLULOSE; CHEMOKINE CXCL10; CHEMOKINES; COMPLEMENT C3B; COMPLEMENT C4B; CULTURE MEDIA, CONDITIONED; CYTOKINES; HUMANS; INTERFERON-BETA; LEUKOCYTES; LIPOPOLYSACCHARIDES; MICROSPHERES; OPSONIN PROTEINS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; STAT1 TRANSCRIPTION FACTOR;

EID: 82655184664     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04490.x     Document Type: Article

References (33)

1. Hanai H, Takeda Y, Eberhardson M etal. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol 2011; 163:50-8.
2. Shimoyama T, Sawada K, Hiwatashi N etal. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apheresis 2001; 16:1-9.
3. Takeda Y, Shiobara N, Saniabadi AR, Adachi M, Hiraishi K. Adhesion dependent release of hepatocyte growth factor and interleukin-1 receptor antagonist from human blood granulocytes and monocytes: evidence for the involvement of plasma IgG, complement C3 and beta2 integrin. Inflamm Res 2004; 53:277-83.
4. Hanai H, Watanabe F, Yamada M etal. Correlation of serum soluble TNF-alpha receptors I and II levels with disease activity in patients with ulcerative colitis. Am J Gastroenterol 2004; 99:1532-8.
5. Hiraishi K, Takeda Y, Shiobara N etal. Studies on the mechanisms of leukocyte adhesion to cellulose acetate beads: an in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte adsorptive apheresis. Ther Apher Dial 2003; 7:334-40.
6. Saniabadi AR, Hanai H, Suzuki Y etal. Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy? J Clin Apher 2005; 20:171-84.
7. Saniabadi AR, Hanai H, Takeuchi K, Bjarnason I, Lofberg R. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial 2003; 7:48-59.
8. Saniabadi AR, Hanai H, Fukunaga K etal. Therapeutic leukocytapheresis for inflammatory bowel disease. Transfus Apher Sci 2007; 37:191-200.
9. Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 2002; 168:3195-204.
10. Lee EY, Lee ZH, Song YW. CXCL10 and autoimmune diseases. Autoimmun Rev 2009; 8:379-83.
11. Law SK, Dodds AW. The internal thioester and the covalent binding properties of the complement proteins C3 and C4. Protein Sci 1997; 6:263-74.
12. Carroll MC. The role of complement and complement receptors in induction and regulation of immunity. Annu Rev Immunol 1998; 16:545-68.
13. Hirano A, Kurita-Taniguchi M, Katayama Y, Matsumoto M, Wong TC, Seya T. Ligation of human CD46 with purified complement C3b or F(ab')(2) of monoclonal antibodies enhances isoform-specific interferon gamma-dependent nitric oxide production in macrophages. J Biochem 2002; 132:83-91.
14. Nguyen KB, Cousens LP, Doughty LA, Pien GC, Durbin JE, Biron CA. Interferon alpha/beta-mediated inhibition and promotion of interferon gamma: STAT1 resolves a paradox. Nat Immunol 2000; 1:70-6.
15. Kurita-Taniguchi M, Fukui A, Hazeki K etal. Functional modulation of human macrophages through CD46 (measles virus receptor): production of IL-12 p40 and nitric oxide in association with recruitment of protein-tyrosine phosphatase SHP-1 to CD46. J Immunol 2000; 165:5143-52.
16. Riley-Vargas RC, Gill DB, Kemper C, Liszewski MK, Atkinson JP. CD46: expanding beyond complement regulation. Trends Immunol 2004; 25:496-503.
17. Cardone J, Le Friec G, Vantourout P etal. Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells. Nat Immunol 2010; 11:862-71.
18. Barchet W, Price JD, Cella M etal. Complement-induced regulatory T cells suppress T-cell responses but allow for dendritic-cell maturation. Blood 2006; 107:1497-504.
19. Kemper C, Verbsky JW, Price JD, Atkinson JP. T-cell stimulation and regulation: with complements from CD46. Immunol Res 2005; 32:31-43.
20. Brinkkoetter PT, Marinaki S, Gottmann U etal. Altered CD46-mediated T cell co-stimulation in haemodialysis patients. Clin Exp Immunol 2005; 139:534-41.
21. Takeda Y, Ohba M, Ueno M, Saniabadi AR, Wakabayashi I. Cellulose acetate beads activate the complement system but inactivate the anaphylatoxins generated. Artif Organs 2010; 34:1144-9.
22. Cuadrado E, Alonso M, de Juan MD, Echaniz P, Arenas JI. Regulatory T cells in patients with inflammatory bowel diseases treated with adacolumn granulocytapheresis. World J Gastroenterol 2008; 14:1521-7.
23. Yokoyama Y, Fukunaga K, Fukuda Y etal. Demonstration of low-regulatory CD25high+CD4+ and high-pro-inflammatory CD28-CD4+ T-cell subsets in patients with ulcerative colitis: modified by selective granulocyte and monocyte adsorption apheresis. Dig Dis Sci 2007; 52:2725-31.
24. Ho HH, Ivashkiv LB. Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation. J Biol Chem 2006; 281:14111-18.
25. Imanguli MM, Swaim WD, League SC, Gress RE, Pavletic SZ, Hakim FT. Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa. Blood 2009; 113:3620-30.
26. Frisullo G, Nociti V, Iorio R etal. T-bet and pSTAT-1 expression in PBMC from coeliac disease patients: new markers of disease activity. Clin Exp Immunol 2009; 158:106-14.
27. Sikorski K, Czerwoniec A, Bujnicki JM, Wesoly J, Bluyssen HA. STAT1 as a novel therapeutical target in pro-atherogenic signal integration of IFNgamma, TLR4 and IL-6 in vascular disease. Cytokine Growth Factor Rev 2011; in press (online publication; DOI: 10.1016/j.cytogfr.2011.06.003).
28. Honda K, Takaoka A, Taniguchi T. Type I interferon gene induction by the interferon regulatory factor family of transcription factors. Immunity 2006; 25:349-60.
29. Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006; 25:383-92.
30. Santer DM, Hall BE, George TC etal. C1q deficiency leads to the defective suppression of IFN-alpha in response to nucleoprotein containing immune complexes. J Immunol 2010; 185:4738-49.
31. Manderson AP, Botto M, Walport MJ. The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 2004; 22:431-56.
32. Rupert KL, Moulds JM, Yang Y etal. The molecular basis of complete complement C4A and C4B deficiencies in a systemic lupus erythematosus patient with homozygous C4A and C4B mutant genes. J Immunol 2002; 169:1570-8.
33. Wu YL, Yang Y, Chung EK etal. Phenotypes, genotypes and disease susceptibility associated with gene copy number variations: complement C4 CNVs in European American healthy subjects and those with systemic lupus erythematosus. Cytogenet Genome Res 2008; 123:131-41.